Cannabinoid and Psychedelic Pharmacology and Drug Development

Cannabinoid and Psychedelic Pharmacology and Drug Development

by Jim Mitchell and Google NotebookLM
ChemistryLife Sciences
Season 1

30 Day FDA and ICH Drug Development Regulations - Day 8 Drug Substance Production (ICH Q7)

Today’s episode explores the intricate world of ICHQ7, the benchmark for manufacturing active pharmaceutical ingredients (APIs). These guidelines form the backbone of pharmaceutical production, ensuring APIs are made to the highest standards of safety and quality. The discussion highlights the critical role of cleanroom environments, advanced equipment, ongoing personnel training, and exhaustive documentation in maintaining product consistency and preventing contamination. Contract manufacturing partners (CDMOs) are explored as key players in this ecosystem, providing specialized expertise throughout the process. The connection between GMPs and the broader drug development pipeline is also examined, showing how they ensure reliable data during pre-clinical studies, clinical trials, and beyond. These practices safeguard the integrity of medications and the safety of patients. This journey through ICHQ7 emphasizes the meticulous systems and standards that underpin every step of pharmaceutical manufacturing. It’s a glimpse into the commitment to quality and precision that brings life-saving treatments to patients worldwide.
S1 · E10
Jan 28, 2025
17:47

30 Day FDA and ICH Drug Development Regulations - Day 9 Drug Product Development

Today’s episode delves into the complex world of drug product development, breaking down the journey from idea to pharmacy shelf. From formulation design and process validation to stability testing, we explore how every step ensures medications are safe, effective, and consistent. We discuss the importance of regulations like CFR Title 21, covering everything from sanitation to bioequivalence for generic drugs, and how these standards build a foundation of trust and quality. Cutting-edge innovations such as tamper-proof opioids and nanoparticle drug delivery systems highlight how science is pushing boundaries to meet modern healthcare challenges. Through meticulous process validation, rigorous testing, and robust documentation, manufacturers and regulators collaborate to protect patients while fostering advancements. This episode captures the dedication behind every pill, showcasing the interplay of science, safety, and innovation that drives progress in pharmaceuticals.
S1 · E11
Jan 28, 2025
14:20

30 Day FDA and ICH Drug Development Regulations - Day 10 Quality by Design (QbD)

This episode unpacks the fascinating world of Quality by Design (QbD) in drug development, guided by ICH Q8 and Q11 principles. We explore how QbD ensures quality is built into every stage of a drug's lifecycle, from identifying critical quality attributes (CQAs) to defining flexible design spaces for manufacturing. Discover the shift from reactive to proactive approaches in pharmaceutical production, leveraging tools like risk assessment, process modeling, and statistical analysis to optimize quality and minimize variability. We also dive into how QbD benefits manufacturers by reducing waste and improving efficiency, while ultimately delivering safer and more effective medications to patients. Join us as we break down the science, innovation, and real-world impact of QbD, showcasing how this approach is revolutionizing the pharmaceutical industry and driving continuous improvement.
S1 · E12
Jan 28, 2025
18:00

30 Day FDA and ICH Drug Development Regulations - Day 11 Analytical Validation (ICH Q2)

This episode dives into the world of analytical validation, focusing on the ICH Q2 guidelines and their role in ensuring reliable data in drug development. We break down critical concepts like accuracy, precision, specificity, and robustness, explaining how each contributes to producing safe and effective medications. We also explore why early drug development relies on verification instead of validation and how this process evolves for biologics, tackling challenges like variability and the need for complex bioassays. We discuss the global regulatory frameworks that govern analytical validation, such as CGMPs and ICH Q2, highlighting their importance in maintaining consistent standards worldwide. Real-world scenarios illustrate how these principles apply across preclinical studies, clinical trials, and manufacturing, ensuring quality and reliability at every stage. Looking ahead, we examine the emerging challenges in analytical validation brought by personalized medicine and advanced therapies like cell and gene treatments. With the need for more sensitive and robust methods, the field continues to evolve, offering exciting opportunities for innovation. This episode provides a comprehensive overview of the science, regulations, and future of analytical validation in the pharmaceutical industry.
S1 · E13
Jan 28, 2025
21:41

30 Day FDA and ICH Drug Development Regulations - Day 12 Control of Impurities (ICH Q3A-Q3E)

This episode takes a closer look at pharmaceutical impurities and the ICH guidelines (Q3A-Q3E) that govern their identification, classification, and control. From organic and inorganic impurities to residual solvents, we explore how these unwanted substances can originate, how they're detected using advanced analytical techniques like mass spectrometry, and how acceptable daily intake (ADI) levels are established to ensure patient safety. We delve into the role of stability testing in managing degradation products and highlight the importance of purge factors in controlling impurities during manufacturing. Computational tools like QSAR models are transforming impurity risk assessments, enabling faster, data-driven predictions of toxicity. For biopharmaceuticals, managing product-related impurities introduces unique challenges due to their complexity and variability. Guidelines like ICH Q5A and Q6B are critical in ensuring the quality of these therapies, while global harmonization efforts strive to maintain consistent regulatory standards across borders. Looking ahead, advancements in analytical technology, computational modeling, and global collaboration are shaping a proactive future for impurity control. This deep dive underscores the immense scientific effort and regulatory commitment that ensure medications are safe and effective for patients worldwide.
S1 · E14
Jan 28, 2025
17:01

30 Day FDA and ICH Drug Development Regulations - Day 13 Mutagenic Impurities (ICH M7)

Mutagenic impurities are a critical concern in pharmaceutical safety, governed by the ICH M7 guidelines. This deep dive explored the complex interplay of science, regulation, and manufacturing processes designed to identify, assess, and control these potentially harmful impurities. Key points included the use of tools like QSAR (Quantitative Structure-Activity Relationship) for predicting the mutagenic potential of impurities based on molecular structure and the calculation of Acceptable Daily Intakes (ADI) to set safety thresholds tailored to a drug's intended use—whether chronic or acute. The discussion highlighted how ICH M7 influences all stages of drug development, from preclinical studies to clinical trials and commercial manufacturing. This includes stringent stability testing to ensure drugs remain safe over time and meticulous documentation via the Common Technical Document (CTD), which ensures traceability and accountability throughout the process. Good Manufacturing Practices (GMPs) provide the overarching framework for quality control, while specific strategies like calculating purge factors and employing multi-step purification processes minimize risks during manufacturing. Real-world examples underscored the iterative nature of drug development, with adjustments made to improve safety and efficacy. Finally, the conversation touched on drug-drug interactions and their role in impurity control, illustrating the delicate balance between therapeutic benefits and potential risks. By integrating advanced analytical technologies, proactive risk assessments, and global harmonization efforts, the industry continues to evolve in its mission to develop safe and effective medications for patients worldwide.
S1 · E15
Jan 28, 2025
23:36

30 Day FDA and ICH Drug Development Regulations - Day 14 Current Good Manufacturing Practices (cGMPs)

Dive into the world of Current Good Manufacturing Practices (CGMPs), the unsung heroes of pharmaceutical manufacturing. This episode unpacks how meticulous documentation, facility design, quality control, and personnel training ensure the safety and efficacy of medications. Learn about the Master Batch Record, FDA oversight, and the critical role of CDMOs in drug production. We also explore how CGMPs adapt to challenges like biopharmaceuticals, personalized medicine, and global harmonization efforts. Discover the intricate systems that protect your health, one pill at a time.
S1 · E16
Jan 28, 2025
15:42

30 Day FDA and ICH Drug Development Regulations - Day 15 Controlled Substances

Dive into the complex world of controlled substances in this episode of Deep Dive. From the meticulous schedules of the Controlled Substances Act to the balancing act between regulation, research, and public safety, we explore how powerful drugs are developed, monitored, and controlled. Learn about the roles of the FDA and DEA, the challenges of manufacturing and distribution, and the growing interest in cannabinoids and psychedelics. We also tackle the vital topics of addiction, harm reduction, and equity, emphasizing the need for compassionate, evidence-based approaches. A thought-provoking look at an ever-evolving landscape!
S1 · E17
Jan 29, 2025
25:05

30 Day FDA and ICH Drug Development Regulations - Day 16 Safety Pharmacology (ICH S7)

Explore the fascinating world of drug safety with a deep dive into ICH S7 guidelines. Discover how rigorous testing, from animal models to cutting-edge tech like in vitro methods and computer simulations, ensures medications are safe for human use. Learn how researchers assess effects on vital systems like the heart, lungs, and nervous system, and how post-market surveillance continues to protect patients after approval. A compelling look at the science, ethics, and collaboration driving safer, more effective treatments!
S1 · E18
Jan 29, 2025
26:21

30 Day FDA and ICH Drug Development Regulations - Day 17 Over-the-Counter (OTC) vs. Prescription Drugs

Join us as we explore the fascinating world of medications in this episode of Deep Dive! From the rigorous regulations behind prescription drugs to the murky waters of nutraceuticals and the rising interest in CBD, we break down what you need to know to navigate the world of health products. Learn about the pathways that bring drugs to market, the safeguards of clinical trials, and how patients and professionals alike contribute to medical advancements. Empower yourself with the knowledge to make informed health decisions—because understanding your medications is key to better health!
S1 · E19
Jan 29, 2025
22:01
2 of 26